Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03489018
Other study ID # QA1075
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date March 21, 2019
Est. completion date December 30, 2024

Study information

Verified date March 2023
Source London School of Hygiene and Tropical Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Before the introduction of pneumonia vaccines in 2000, between 700,000 - 1 million children died each year as a result of infection with the bacteria Streptococcus pneumoniae and the resulting diseases, namely, meningitis, sepsis and pneumonia. Most of the deaths were in Africa and Asia. Where the vaccines have been introduced, they have been highly effective and have already reduced disease. However, at 10 USD per child, they are not affordable to most low-income countries without financial support from Gavi, the Vaccine Alliance. This project aims to assess whether lower doses of the two commercially available pneumonia vaccines can protect Kenyan infants as well as the full dose. The results could be used to increase the affordability of the pneumonia vaccine, and enable delivery of the vaccine to continue in the absence of Gavi support.


Description:

Background: PCV is currently the most expensive vaccine in the routine immunisation schedule in Gavi-supported countries. This study aims to provide evidence which may enable a substantial decrease in the cost of PCV programmes, therefore increasing the sustainability of PCV programmes in low and middle income countries (LMICs). We propose to assess whether fractional (20% and 40%) doses of pneumococcal conjugate vaccine (PCV10 and PCV13) in a 2p+1 schedule (2 primary doses followed by a booster dose) induce non-inferior immunogenicity and effects on vaccine-serotype carriage when compared to the full dose. These lower doses could convert new 4-dose vials of PCVs into 10- or 20-dose vials, ready for immediate implementation in LMIC programmes. Primary objective: Non-inferior immunogenicity at 1-month post-boost (10 months of age). Non-inferiority will be reached if the lower CI around the ratio of geometric mean concentrations (GMC) of IgG (fractional/full dose) is >0.5 (i.e. the 2-fold criterion). Secondary objectives: Non-inferior immunogenicity at 1-month post-primary series (18 weeks of age). Non-inferiority will be achieved if the lower limit of the 95% confidence interval (CI) around the difference in the proportion of 'responders', children with IgG>=0.35 mcg/ml, (fractional dose group - full dose group) is >-10% for at least 8 of the 10 vaccine types in the PCV10 arms and at least 10 of the 13 vaccine types in the PCV13 arms. The opsonophagocytic activity of the antibody response to 7 serotypes after full/ fractional doses at the 1-month post-boost time point. The direct vaccine effectiveness of full/fractional doses of PCV13 against carriage of serotypes 6A and 19A, with primary analyses at 18 months of age and secondary analyses at 9 months of age. The proportion of children with evidence of vaccine-serotype carriage by trial arm at 9 and 18 months of age. The geometric mean concentration (GMC) of serotype-specific IgG after the primary series of the 2p+1 schedule, prior to boost, at 9 months of age. The geometric mean concentration (GMC) of serotype-specific IgG after three doses of vaccine in a 2p+1 schedule at 18 months of age. The carriage prevalence at 9 and 18 months of age and IgG concentrations at 4 weeks after the primary series after full dose of PCV10 in a 3p+0 schedule, and full/ fractional doses of PCV10/13 in a 2p+1 schedule. Trial design: A phase IV individually-randomised controlled trial of full or fractional (20% or 40%) doses of PCV10/ PCV13, given as a 3-dose schedule to infants: 2 doses at 6 and 14 weeks of age and a booster dose at 9 months (the 2p+1 schedule) or 3 full doses at 6, 10 and 14 weeks of age (the 3p+0 schedule). At 6-8 weeks of age, 300 infants will be enrolled at random into each of the seven trial arms and followed until 18 months of age. The seven trial arms: A. Full dose PCV13 vaccination in a 2p+1 schedule. B. 40% fractional dose PCV13 vaccination in a 2p+1 schedule. C. 20% fractional dose PCV13 vaccination in a 2p+1 schedule. D. Full dose PCV10 vaccination in a 2p+1 schedule. E. 40% fractional dose PCV10 vaccination in a 2p+1 schedule. F. 20% fractional dose PCV10 vaccination in a 2p+1 schedule. G. Full dose PCV10 vaccination in a 3p+0 schedule. This arm would represent the current vaccine and schedule in the Kenyan routine immunisation programme and would act as an additional comparison arm. Study procedures: No study procedures will be conducted without prior parental informed consent. Participants in trial arms A-F will provide 3 or 5 blood samples in the course of the trial at enrolment, 4 weeks post-primary series (approximately 18 weeks of age) and 4 weeks post-boost (approximately 10 months of age); additionally a random selection of half the participants will contribute blood samples pre-boost (9 months of age) and at the last study visit (18 months of age). Participants in trial arm G will provide 2 blood samples (at enrolment and at 4 weeks post-primary series (approximately 18 weeks of age). All participants will provide 2 nasopharyngeal swabs at approximately 9 and 18 months of age and contribute safety data.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 2100
Est. completion date December 30, 2024
Est. primary completion date September 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Weeks to 8 Weeks
Eligibility Inclusion Criteria: - Healthy infants aged 6-8 weeks of age (HIV positive or negative but with no symptoms of current clinical immunosuppression i.e. HIV infection at WHO clinical stage 1); - Parents are willing to provide informed consent for their child to participate in the study - Parents and infant are likely to remain in the study area until the infant is 18 months of age and comply with study requirements including the requirement to return to the same health facility to obtain all other childhood vaccines. Exclusion Criteria: - Infants >8 weeks of age at time of enrolment - Signs or symptoms of immunosuppression or HIV infection clinical stage 2 or above. - Acute illness (e.g. febrile disease) on the day of vaccination - Contraindications precluding vaccination (e.g. hypersensitivity to any component of the vaccine, including diphtheria toxoid) - Previous PCV vaccination - Family are planning to migrate out of the study areas before the end of the study follow-up - Family are planning to obtain the subsequent vaccine doses of the routine immunisation schedule elsewhere and therefore their child may receive a full dose under the routine vaccination programme.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
PCV10
Experimental arms will receive a lower dose of the intervention than the marketed dose.
PCV13
Experimental arms will receive a lower dose of the intervention than the marketed dose.

Locations

Country Name City State
Kenya KEMRI Wellcome Trust Research Programme Kilifi

Sponsors (6)

Lead Sponsor Collaborator
London School of Hygiene and Tropical Medicine Bill and Melinda Gates Foundation, KEMRI-Wellcome Trust Collaborative Research Program, National Institute of Health Research (NIHR) Mucosal Pathogens Research Unit (MPRU), University College, London, Wellcome Trust

Country where clinical trial is conducted

Kenya, 

Outcome

Type Measure Description Time frame Safety issue
Other Immunogenicity: the geometric mean concentration (GMC) of serotype-specific IgG IgG GMCs elicited post-primary series 4-weeks post-primary series (approximately 18 weeks of age)
Other Safety: the prevalence of adverse events following immunisation by arm The proportion fo children with adverse events following immunisation by arm Infants 6weeks-18 months of age
Other Immunogenicity: The geometric mean concentration (GMC) of serotype-specific IgG after the primary series of the 2p+1 schedule, prior to boost (9 months of age) and at the end of study follow-up at 18 months of age. IgG GMCs at 9 and 18 months of age Approximately 9 and 18 months of age
Primary Immunogenicity: The ratio of IgG GMCs at 1-month post boost The ratio of the geometric mean concentrations of IgG after vaccination with 3 full or fractional doses of PCV 4-weeks post-boost (approximately 10 months of age)
Secondary Immunogenicity: the proportion of children who 'seroconvert' to vaccine-serotypes after vaccination The proportion of children with vaccine-serotype specific IgG antibody concentrations more than or equal to 0.35 mcg/ml after vaccination 4-weeks post-primary series (approximately 18 weeks of age)
Secondary The proportion of children with evidence of vaccine-serotype carriage Vaccine-type carriage prevalence across arms Approximately 18 months of age
Secondary The proportion of children with evidence of vaccine-serotype carriage Vaccine-type carriage prevalents across arms Approximately 9 months of age
Secondary The direct vaccine effectiveness of full/fractional doses of PCV13 against carriage of serotypes 6A and 19A The direct effectiveness of full/fractional doses of PCV13 in preventing carriage of serotypes 6A and 19A compared to that of full dose PCV10 Approximately 18 months of age
Secondary Opsonophagocytic activity of vaccine-induced antibody to 4 serotypes Functionality of the antibody response Approximately 18 months of age
See also
  Status Clinical Trial Phase
Completed NCT02463539 - Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis N/A
Completed NCT03095326 - Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia Phase 4
Completed NCT02260882 - Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902) Phase 4
Completed NCT02572635 - A Phase I Study to Evaluate the Safety and Immunogenicity of PnuBioVax Phase 1
Completed NCT01654263 - A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine Phase 2
Completed NCT01531322 - A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects Phase 1
Completed NCT00496093 - Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011) Phase 3
Completed NCT02062281 - Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults Phase 4
Completed NCT00133549 - 9-valent CRM 197 Pneumococcal Phase 2
Completed NCT03467984 - A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants Phase 2
Recruiting NCT02463578 - Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis N/A
Completed NCT00535730 - ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED) Phase 3
Completed NCT02558751 - Pneumonia Vaccine in Aging HIV Positive Individuals Phase 0
Completed NCT02515240 - Immune Response to Pneumococcal Vaccination in HIV Infected Individuals Phase 0
Completed NCT00560950 - Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007) Phase 3
Completed NCT05425732 - Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3) Phase 3
Not yet recruiting NCT03549208 - A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Phase 1
Completed NCT03619252 - Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Phase 4
Not yet recruiting NCT03341195 - Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan N/A
Recruiting NCT06177912 - A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) Phase 3